文献速递乳腺癌妇科肿瘤

2012-2019年乳腺癌或卵巢癌女性胚系基因检测及结果的时间趋势

Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
PubMed 文献 · J Clin Oncol · 2021-02-09

该研究基于SEER登记数据,分析2013-2017年加州和佐治亚州诊断为乳腺癌或卵巢癌女性的临床胚系检测趋势。结果显示仅25.2%乳腺癌和34.3%卵巢癌患者接受检测,每年检测率增2%但检测基因数增28%;VUS率从11.2%升至26.8%,少数族裔更高;大多数PV位于20个乳腺癌/卵巢癌相关基因。

要点

  • 卵巢癌检测率仅34.3%,远低于推荐,检测缺口持续存在。
  • VUS率随时间翻倍(11.2%→26.8%),少数族裔患者显著更高。
  • 大多数PV位于20个乳腺癌/卵巢癌相关基因,检测其他基因主要返回VUS。

核心结论

  • 卵巢癌患者检测缺口持续存在(34.3%检测 vs 几乎全部推荐)。
  • 增加检测基因数扩大了VUS结果的种族或民族差异。
  • 大多数PV位于20个乳腺癌/卵巢癌相关基因,检测其他基因主要产生VUS。

研究设计与样本

  • SEER登记中2013-2017年加州或佐治亚州诊断的年龄≥20岁乳腺癌或卵巢癌女性。
  • 记录链接至2019年的临床胚系检测结果。
  • 分析检测趋势、VUS率和PV率。

主要发现

  • 187,535例乳腺癌中25.2%检测,14,689例卵巢癌中34.3%检测。
  • 每年检测率增加2%,检测基因数增加28%。
  • 2017年乳腺癌:BRCA1/2 PV 5.2%、VUS 0.8%;乳腺癌/卵巢癌相关基因PV 3.7%、VUS 12.0%;其他可操作基因PV 0.6%、VUS 0.5%;其他基因PV 0.3%、VUS 2.6%。
  • 2017年卵巢癌:BRCA1/2 PV 11.0%、VUS 0.9%;乳腺癌/卵巢癌相关基因PV 4.0%、VUS 12.6%;其他可操作基因PV 0.7%、VUS 0.4%;其他基因PV 0.3%、VUS 0.6%。
  • VUS率从2013年诊断的11.2%升至2017年诊断的26.8%;少数族裔更高(亚裔47.8%、黑人46.0% vs 非西班牙裔白人24.6%;P < .001)。

关键数值与推荐

  • 乳腺癌患者中25.2%接受检测,卵巢癌患者中34.3%接受检测。
  • 2017年乳腺癌BRCA1/2 PV为5.2%,卵巢癌BRCA1/2 PV为11.0%。
  • VUS率2013年11.2%,2017年26.8%。
  • 少数族裔VUS率:亚裔47.8%、黑人46.0%,非西班牙裔白人24.6%(P < .001)。

临床怎么用

  • 应关注对具有指征的患者进行检测,而非单纯增加检测基因数。
  • 卵巢癌患者检测率远低于推荐,需改进转诊和检测实施。
  • 解读VUS时需考虑种族或民族差异,避免不必要干预。

局限性

  • 仅纳入加州和佐治亚州SEER登记区域,外推性受限。
  • 检测数据来自临床链接,可能存在未记录检测。
  • 研究为观察性设计,无法推断因果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Genetic testing is important for breast and ovarian cancer risk reduction and treatment, yet little is known about its evolving use. METHODS: SEER records of women of age ≥ 20 years diagnosed with breast or ovarian cancer from 2013 to 2017 in California or Georgia were linked to the results of clinical germline testing through 2019. We measured testing trends, rates of variants of uncertain significance (VUS), and pathogenic variants (PVs). RESULTS: One quarter (25.2%) of 187,535 patients with breast cancer and one third (34.3%) of 14,689 patients with ovarian cancer were tested; annually, testing increased by 2%, whereas the number of genes tested increased by 28%. The prevalence of test results by gene category for breast cancer cases in 2017 were BRCA1/2, PVs 5.2%, and VUS 0.8%; breast cancer-associated genes or ovarian cancer-associated genes (ATM, BARD1, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, and TP53), PVs 3.7%, and VUS 12.0%; other actionable genes (APC, BMPR1A, MEN1, MUTYH, NF2, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SMAD4, TSC1, TSC2, and VHL) PVs 0.6%, and VUS 0.5%; and other genes, PVs 0.3%, and VUS 2.6%. For ovarian cancer cases in 2017, the prevalence of test results were BRCA1/2, PVs 11.0%, and VUS 0.9%; breast or ovarian genes, PVs 4.0%, and VUS 12.6%; other actionable genes, PVs 0.7%, and VUS 0.4%; and other genes, PVs 0.3%, and VUS 0.6%. VUS rates doubled over time (2013 diagnoses: 11.2%; 2017 diagnoses: 26.8%), particularly for racial or ethnic minorities (47.8% Asian and 46.0% Black, v 24.6% non-Hispanic White patients; P < .001). CONCLUSION: A testing gap persists for patients with ovarian cancer (34.3% tested v nearly all recommended), whereas adding more genes widened a racial or ethnic gap in VUS results. Most PVs were in 20 breast cancer-associated genes or ovarian cancer-associated genes; testing other genes yielded mostly VUS. Quality improvement should focus on testing indicated patients rather than adding more genes.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kurian AW, Ward KC, Abrahamse P, et al. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. J Clin Oncol. 2021. PMID: 33560870. doi:10.1200/JCO.20.02785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。